TROPION-Breast02: First-line Dato-DXd shows superiority over chemotherapy in patients with TNBC ineligible for immunotherapy

ESMO 2025

Breast Cancer

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

ESMO 2025

Genitourinary Cancer

TROPION-PanTumor03: Dato-DXd plus rilvegostomig shows promising activity in patients with advanced urothelial cancer

Lung, Respiratory and Thoracic Cancer

First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC

Clin Cancer Res

Pecci F, Li H, Di Federico A, Wu J, Chen H, Gariazzo E, Mantuano F, Garbo E, Aldea M, Santo V, Gibbons D, Tran H, Paoloni F, Rossato de Almeida G, Metro G, De Giglio A, Gelsomino F, Wang X, Tiseo M, Rotow J, Ardizzoni A, Lee JJ, Awad MM, Addeo A, Hong L, Negrao MV, Janne PA, Heymach JV, Zhang J, Ricciuti B, Le X

doi: 10.1158/1078-0432.CCR-25-1735

Lung, Respiratory and Thoracic Cancer

Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis

Semin Oncol

Bertaglia V, Petrelli F, Dottorini L, Carnio S, Morelli AM, Nepote A, Maccioni A, Scartozzi M, Solinas C, Novello S

doi: 10.1053/j.seminoncol.2024.11.001

ELCC 2025

Lung, Respiratory and Thoracic Cancer

TROPION-Lung01: Favorable QoL outcomes with Dato-DXd in patients with pretreated advanced or metastatic NSCLC

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

SABCS 2024

Breast Cancer

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

Lung, Respiratory and Thoracic Cancer

Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy

J Thorac Oncol

Wiesweg M, Alaffas A, Rasokat A, Saalfeld FC, Rost M, Assmann C, Herster F, Hilbrandt M, Griesinger F, Kron A, Roeper J, Glanemann F, Kropf-Sanchen C, Reck M, Kulhavy J, Stenzinger A, Wolf J, Sebastian M, Schuler M, Wermke M, Frost N, Kopp HG, Christopoulos P, Scheffler M

doi: 10.1016/j.jtho.2025.04.016

Breast Cancer

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

Eur J Cancer

Michel LL, Ziegler P, Kreis P, Hartkopf AD, Wallwiener M, Häberle L, John N, Kolberg HC, Hadji P, Tesch H, Ettl J, Lüftner D, Müller V, Belleville E, Wimberger P, Enzinger HM, Huebner H, Uhrig S, Hack CC, Krabisch P, Fasching PA, Wuerstlein R, Untch M, Ditsch N, Hein A, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Fehm TN, Schneeweiss A, Goossens C, Engler T

doi: 10.1016/j.ejca.2025.115689

Related content

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

TROPION-PanTumor03: Dato-DXd plus rilvegostomig shows promising activity in patients with advanced urothelial cancer

First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC

Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis

TROPION-Lung01: Favorable QoL outcomes with Dato-DXd in patients with pretreated advanced or metastatic NSCLC

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

PADMA: First-line palbociclib plus ET improves TFF and PFS versus chemotherapy in patients with high-risk HR-positive/HER2-negative metastatic breast cancer

Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy

Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer